Article Information
History
- January 10, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ilya Kister1,
- Yury Patskovsky2,
- Ryan Curtin2,
- Jinglan Pei3,
- Katherine Perdomo1,
- Zoe Rimler1,
- Iryna Voloshyna2,
- Marie I. Samanovic4,
- Amber R. Cornelius4,
- Yogambigai Velmurugu2,
- Samantha Nyovanie2,
- Joseph Kim2,
- Ethan Tardio2,
- Tamar E. Bacon1,
- Lana Zhovtis Ryerson1,
- Pranil Raut3,
- Rosetta Pedotti5,
- Kathleen Hawker3,
- Catarina Raposo5,
- Jessica Priest3,
- Mark Cabatingan3,
- Ryan C. Winger3,
- Mark J. Mulligan4,
- Michelle Krogsgaard2,#,* and
- Gregg J. Silverman5,#,*
- 1NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, NY, 10016, USA
- 2Laura and Isaac Perlmutter Cancer Center and Department of Pathology, New York University Grossman School of Medicine, New York, NY, 10016, USA
- 3Genentech, Inc., South San Francisco, CA, USA
- 4NYU Langone Vaccine Center, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA
- 5F. Hoffmann-La Roche Ltd, Basel, Switzerland
- 6Division of Rheumatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA
- ↵#Corresponding authors Michelle Krogsgaard, PhD Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA Michelle.Krogsgaard{at}nyulangone.org, Gregg Silverman, MD 435 E 30th Street, Room 517 Department of Medicine, NYU Grossman School of Medicine New York New York 10016 Gregg.Silverman{at}nyulangone.org
Posted January 10, 2022.
Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study
